Table 2 Study characteristics
Number of studies (n) | Percentage of total studies (%) | |
|---|---|---|
Sub-Saharan region | ||
South | 16 | 30.2 |
West | 16 | 30.2 |
East | 14 | 26.4 |
Middle | 7 | 13.2 |
Country | ||
South Africa | 14 | 26.4 |
Nigeria | 10 | 18.9 |
Cameroon | 7 | 13.2 |
Kenya | 5 | 9.4 |
Uganda | 4 | 7.5 |
Ghana | 3 | 5.7 |
Botswana | 2 | 3.8 |
Tanzania | 1 | 1.9 |
Cote d’Ivoire | 1 | 1.9 |
Zambia | 1 | 1.9 |
Gambia | 1 | 1.9 |
Mozambique | 1 | 1.9 |
Malawi | 1 | 1.9 |
Madagascar | 1 | 1.9 |
Mali | 1 | 1.9 |
Publication date | ||
1996–2000 | 1 | 1.9 |
2001–2005 | 2 | 3.8 |
2006–2010 | 8 | 15.1 |
2011–2017 | 42 | 79.2 |
Study design | ||
Cross-sectional | 34 | 64.2 |
Pre-post test | 10 | 18.9 |
Randomized control trial | 8 | 15.1 |
Nonrandomized control trial | 1 | 1.9 |
Prevention tool | ||
VIA | 19 | 35.8 |
HPV DNA or RNA test | 15 | 28.3 |
Pap smear | 13 | 24.5 |
HPV vaccine | 9 | 17.0 |
Digital imaging | 9 | 17.0 |
VILI | 9 | 17.0 |
Colposcopy | 7 | 13.2 |
Cryotherapy | 5 | 9.4 |
LEEP | 5 | 9.4 |
Biopsy | 5 | 9.4 |
Unspecified screening | 5 | 9.4 |
Implementation strategy | ||
Educate | 38 | 71.7 |
Restructure | 26 | 49.1 |
Quality | 13 | 24.5 |
Finance | 5 | 9.4 |
Plan | 1 | 1.9 |
Attend to policy context | 0 | 0.0 |
Implementation outcome | ||
Penetration | 33 | 62.3 |
Acceptability | 15 | 28.3 |
Fidelity | 14 | 26.4 |
Feasibility | 8 | 15.1 |
Adoption | 6 | 11.3 |
Sustainability | 2 | 3.8 |
Cost | 1 | 1.9 |
Appropriateness | 0 | 0.0 |
Quality assessment | ||
Poor | 20 | 37.7 |
Fair | 22 | 41.5 |
Good | 11 | 20.8 |